Corixa (CRXA)-noch nie gehört? dann mal anschauen - 500 Beiträge pro Seite

[tgfn]

bis gestern hatte ich auch noch keine ahnung, wer oder was corixa ist. auf alle fälle habe ich mir heute diese aktie zugelegt.
macht eure research. besonderes augenmerk auf
pipeline
clinical trials (verschieden produkte in verschiedenen phasen, könnte schönen lauf geben)
kreditlinie (finanziert von einer gruppe um bill gates)
ceo: steven gillis (ex-imclone)
QIII-revenue-steigerung um 328% gegenüber QIII98
neue zahlen müßten bald kommen, habe bis jetzt noch nicht rausfinden könne wann.
sektor (vaccine zur bekämpfung verschiedener krankheiten) boomt gerade
aktie läuft im moment gut, ist auch noch nicht zu stark gestiegen. (cap ca. 500mill$)

gruß tgfn

[tgfn]

ist zwar vom november, trotzdem einige nützliche facts drin.
vaccine gegen melanom in canada zugelassen, entscheid über zulassung in usa steht kurz bevor
auflistung anderer vaccine-trials
Corixa stock rises as Canada approves
melanoma vaccine

by Tyrone Beason
Seattle Times business reporter

Corixa stock rose 7 percent today on news that its melanoma
drug Melacine has won approval in Canada. Melacine becomes
the world`s first commercially available cancer vaccine.

The company`s shares were up $1 to $15.125 in late trading
today.

The Seattle-based company acquired the drug when it took over
Ribi Immunochem Research. Corixa`s partner in the Melacine
program is Schering-Plough.

Melanoma is the most deadly form of skin cancer. The Melacine
treatment - a mixture of broken tumor cells and a stimulating agent
called Detox - tricks the body`s immune system into attacking the
cancer cells.

The drug is much less toxic than chemotherapy, said Mark
McDade, Corixa`s president and chief operating officer.

The results of late-stage clinical trials with Melacine in the United
States, due for completion next year, will determine how strongly
Corixa pushes the drug for use in this country, McDade said,
noting different nations have different expectations for such tests.

Besides Melacine, Corixa`s extensive pipeline includes other
cancer vaccines. The list features an experimental breast-cancer
vaccine and a dozen drugs in clinical trials that are promising in
their own right and deserve further investment, said Thomas Dietz,
an analyst at Pacific Growth Equities. That may be another factor
determining how much money Corixa pumps into Melacine, Dietz
said.


gruß tgfn

[tgfn]

nochmal hallo

hier eine austellung von dem zeugs, an dem corixa gerade arbeitet. hoffentlich wird die formartierung übernommen.

earch results for: ([Company] contains corixa)


Developer / Marketer(s)
Product / Indication
IND
I
/
II
/
III
PLA/NDA
FDA Act.
MKT

RIBI Immunochem (Corixa) /
Melacine / hepatitis B
III





1999

Anergen (Corixa) / N.V. Organon
AnergiX.RA / rheumatoid arthritis
I
4/97
7/98

RIBI Immunochem (Corixa) / Schering-Plough
Melacine / melanoma therapeutic vaccine
P/N





12/91
7/97

Corixa /
/ Candida albicans infections
Pre

Anergen (Corixa) / Novo Nordisk
AnergiX / inflammatory bowel disease (IBD)
L

Corixa / Zenyaku Kogyo
P-vac (PVAC) / psoriasis
I/II


1998

RIBI Immunochem (Corixa) / Biomira
Detox / melanoma combo with Theratope
P/N






1998

RIBI Immunochem (Corixa) /
Melacine / herpes
III





1999

Corixa / Japan Tobacco, Zambon
/ Lung cancer
L

Anergen (Corixa) / Novo Nordisk
AnergiX / multiple sclerosis (MS)
I/II
11/95

12/95

Anergen (Corixa) /
AnervaX / multiple sclerosis (MS)
Pre

RIBI Immunochem (Corixa) / SmithKline
Detox / melanoma combo with Intron A
III







RIBI Immunochem (Corixa) / RIBI Immunochem
MPL-C / reduce reperfusion injury following CABG
II





RIBI Immunochem (Corixa) / Schering-Plough
Melacine / prevention of melanoma recurrence
III





1998

Corixa /
LelF vaccine / drug-resistant mucosal leishmaniasis
I

1999

Corixa /
/ Breast, pancreatic and colon cancers
Pre

Corixa / SmithKline Beecham
/ vaccine for breast and ovarian cancer
I

3/99

Anergen (Corixa) / Corixa
AnervaX / therapeutic vaccine for rheumatoid arthritis
II
1/94
5/94

4/96

Anergen (Corixa) / Organon (Akzo)
AnergiX & gp-39 peptide / rheumatoid arthritis
Pre

Anergen (Corixa) / Novo Nordisk
AnergiX / myasthenia gravis (MG)
Pre

Anergen (Corixa) /
AnerVax / Type I (juvenile onset) diabetes
L

Anergen (Corixa) / Novo Nordisk
AnergiX / insulin dependent diabetes mellitus (Type I)
Pre



:

[pollyanna]

Hallo tgfn,

du warst wohl der einzigste Käufer von corixa gestern.
Ich glaube so ging es mir vorgestern fast auch mit qlt.

Vielen Dank für den guten Tip.

Ich habe auch noch nie was von
der Firma gehört und werde dieses Wochenende mal recherchieren.

Ein Interview mit Steven (www.twst.com/crxa.html) hat mir jedenfalls
schon sehr gute Infos geliefert. Auch die Paper von ihm sind nicht
ohne. Der Knabe hat was auf dem Kasten. Das er von Immunex kommt
und nebenher noch im scientific advisory board von medarex sitzt
spricht für sich.Die Pipeline der Firma ebenfalls.

Mal schauen was sonst noch zu erfahren ist.

[tgfn]

das hat die aktie nicht verdient, daß man sie soweit hinten im board suchen muß. heute mit immerhin 10% plus. und das bei dem umfeld.

gruß tgfn

[Rubininvest]

Corixa...

hmmmmm , koennte was werden , in der Tat...
welches ca. Marktpotential haben eigentlich die Vaccines gegen
a) rheumatoid arthritis
b) multiple sclerose

Danke

Regards
Rubininvest

[tgfn]

hallo rubininvest

wenn das zeugs von corixa was taugt, dann besteht hier ein gewaltiges potential. genau zahlen sind schwierig, am besten schaut man sich die zahlen derjenigen firmen an, die ein ähnliches mittel auf dem markt haben.

gruß tgfn

[tgfn]

und ich sach noch: vergeßt mir corixa nicht, die sind am laufen

gruß tgfn

[tgfn]

und noch eines



Corixa and Genset Collaborate to Sequence
Microbial Genome

PR Newswire - February 08, 2000 08:16

SEATTLE, and PARIS, Feb. 8 /PRNewswire/ -- Corixa Corporation (Nasdaq:
CRXA), a research-and development-based biotechnology company, and Genset
(Nasdaq: GENXY, Nouveau Marche: GENSET), a global genomics company,
today announced that the companies have entered into an agreement pursuant to
which Genset will sequence the genome of an undisclosed organism.

"We are excited to enter into this new collaboration with Genset," stated Mark
McDade, President and Chief Operating Officer of Corixa. "Genset`s rapid and
accurate sequencing and annotation capabilities, coupled with the prospect of
working together in other important fields tied to our antigen discovery capabilities,
were important factors in moving forward with this agreement. From the data
generated, Corixa will seek to develop proprietary immunotherapeutic products
including, but not limited to, vaccines and antibody-based products targeting an
important infectious organism."

Under the terms of the agreement, Corixa will provide certain materials related to
the undisclosed organism to Genset, and Genset expects to use its high-throughput
sequencing and bioinformatics production capacity to rapidly deliver a
fully-sequenced genome in exchange for undisclosed payments. Financial details
have not been disclosed by either party.

Pascal Brandys, Chairman & CEO of Genset said, "This agreement confirms the
broad potential of our industrial-scale genomics platform and our capacity to
generate additional revenue streams from innovative applications. We hope this
initial relationship with Corixa will lead to additional larger cooperative projects
taking full advantage of our gene and polymorphism discovery platform."

About Corixa

Corixa is a research- and development-based biotechnology company committed
to treating and preventing diseases by understanding and directing the immune
system. Corixa applies its expertise in immunology and its proprietary technology
platforms to the discovery and development of vaccine and other antigen-based
products. The company partners with innovative developers and marketers of
pharmaceuticals and diagnostic products to make its products available to patients
around the world. Corixa was founded in 1994 and is headquartered in Seattle,
Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. For
more information, please visit Corixa`s website at www.corixa.com or call the
company`s investor relations information line at 1-877-4CORIXA
(1-877-426-7492).

About Genset

Genset is a global genomics company that integrates state-of-the-art genomic and
molecular biology technologies to provide pharmaceutical companies with patented
genomics information relevant for the discovery, development and marketing of
novel therapeutics. The Company`s objective is to enter into multiple focused
strategic partnerships to assist pharmaceutical companies throughout the drug life
cycle. Its commercial portfolio includes its gene discovery programs in CNS
disorders, cardiovascular diseases, obesity and metabolic disorders; its
pharmacogenomics programs for high-throughput target validation and drug
response; and its gene libraries. Genset`s news releases are available on the
Company`s website at http://www.genxy.com.

Forward-Looking Statements

Except for the historical information presented, certain matters discussed in this
press release are forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially from any future
results, performance or achievements expressed or implied by such statements.
Such risks and uncertainties include Corixa`s failure to develop any products using
the information generated by Genset and other risks detailed from time to time in
Corixa`s public disclosure filings with the U.S. Securities and Exchange Commission
(SEC), including the Annual Report on Form 10-K for the fiscal year ended
December 31, 1998, the Form 8-K filed on April 23, 1999, the Company`s
Registration Statement on Form S-4, filed on August 12, 1999, and the Quarterly
Report on Form 10-Q for the quarter ended September 30, 1999. Copies of
Corixa`s public disclosure filings with the Securities and Exchange Commission
(SEC) are available from its investor relations department.

SOURCE Corixa Corporation

/CONTACT: Jim DeNike, Investor Relations of Corixa Corporation,
206-754-5716, [e-mail], or Jesse Ciccone, Press Relations of
FitzGerald Communications Inc., 415-986-9500, [e-mail], or
Philippe Rousseau, Investor Relations of Genset SA, [phone],
[e-mail]/

gruß tgfn

[tgfn]

und wieder 10%. bin mal gespannt, wie lange ich noch der einzige deutsche corixa-aktionär bin.

gruß tgfn

[tgfn]

hallo

momentan zwischen 30 und 50% nach oben. hier ist der grund:

Wednesday February 9, 8:31 am Eastern Time

Company Press Release

SOURCE: Corixa Corporation

Incyte and Corixa Enter Into Genomic Partnership For Vaccine Discovery
Through Access To LifeSeq Gold

PALO ALTO, Calif., and SEATTLE, Feb. 9 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY - news), a leading provider of genomic information,
and Corixa Corporation (Nasdaq: CRXA - news), a research- and development-based biotechnology company, announced today an agreement in which Corixa will
gain access to Incyte`s LifeSeq® Gold database for use in vaccine, therapeutic monoclonal antibody, and diagnostics development.

As a LifeSeq Gold subscriber, Corixa will have access to Incyte`s extensive patent portfolio, which currently contains 490 issued and allowed full-length gene
patents. Under the terms of the agreement, Incyte could receive future milestone payments and royalties on sales of Corixa products that may be developed with
Incyte technology and database information. Financial terms were not disclosed.

With an estimated 130,000 expressed genes, LifeSeq Gold will provide Corixa researchers with a precise and comprehensive view of human genes. Incyte has
developed and implemented state-of-the-art template-based assembly algorithms into LifeSeq Gold, enabling researchers to focus on gene structure rather than
sequence by collapsing data complexity. Finally, Incyte`s assembly process increases sensitivity in distinguishing closely-related sequences, and organizes ESTs into a
gene-centric rather than sequence-centric database.

``We believe access to LifeSeq Gold will be a powerful tool for further accelerating our antigen discovery efforts, enabling even more rapid development of
immunotherapies to treat a number of diseases,`` said Steve Reed, Ph.D., Chief Scientific Officer and Executive Vice President of Corixa.

``Alliances with biotechnology companies like Corixa are an integral part of broadening our reach within the scientific community,`` said Roy A. Whitfield, Chief
Executive Officer of Incyte. ``Corixa has a wealth of expertise and understanding in developing products that affect the immune system, and we`re pleased to be
aiding them in their discovery and development of new vaccines, novel monoclonal antibodies, and diagnostics through access to LifeSeq Gold.``

About Corixa

Corixa is a research- and development-based biotechnology company committed to treating and preventing diseases by understanding and directing the immune
system. Corixa applies its expertise in immunology and its proprietary technology platforms to the discovery and development of vaccine and other antigen-based
products. The company partners with innovative developers and marketers of pharmaceuticals and diagnostic products to make its products available to patients
around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. For
more information, please visit Corixa`s website at www.corixa.com or call the company`s investor relations information line at 1-877-4CORIXA (1-877-426-7492).

Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the ``safe
harbor`` provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause
actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Such risks and uncertainties include;
possible delays of failure by Corixa to discover, develop and/or commercialize any technology related to Incyte`s LifeSeq Gold database, and other risks detailed
from time to time in Corixa`s public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including Corixa`s Annual Report on Form 10-K for
the fiscal year ended December 31, 1998, Corixa`s Form 8-K filed on April 23, 1999, Corixa`s Registration Statement on Form S-4 filed on August 12, 1999, and
Corixa`s Quarterly Report on Form 10-Q for the quarter ended September 30, 1999. Corixa disclaims any intent or obligation to update these forward- looking
statements. Copies of Corixa`s public disclosure filings with the Securities and Exchange Commission (SEC) are available from its investor relations department.

About Incyte Pharmaceuticals, Inc.

Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of
disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and
services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene
discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more
information, visit Incyte`s web site at www.incyte.com.

Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the ``safe
harbor`` provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause
actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte`s SEC reports, including its Quarterly Report on Form 10-Q
for the quarter ended September 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements.

SOURCE: Corixa Corporation

gruß tgfn

[markusmao]

Hallo tgfn,

Du scheinst hier wohl Deinen eigenen Thread zu haben und eine
Art zwiegespräch mit Dir zu führen.

Ich gratuliere Dir jedenfalls zur Perfomance der Aktie,
heute zwar ein bischen zurück, aber ich wünsche Dir, daß
Du noch viel spaß haben wirst mit dem titel. Für einen einstieg
scheint mir das Ding momentan etwas zu hoch.

Also Alter, Hals und Beinbruch, Deine Arbeit wird belohnt.

[tgfn]

hallo markusmao

gibt`s ja gar nicht. hat sich ja doch einer in den fred hier verirrt. naja, ich poste die ganzen news eigentlich an mich selber. am nächsten tag lese ich dann den fred, und freue mich über die guten neuigkeiten. ich könnte aber wetten, daß mehr leute sich für corixa interessieren würden, wenn ich den fred sowas wie corixa, 1000% oder sowas geschrieben hätte.
mal im ernst.mit soviel news konnte keiner rechnen, ist ein zufall daß ich zu einem relativ niedrigen kurs eingestiegen bin. aber angesichts der pipeline sollte man corixa schon weiterhin im auge behalten. die haben irgendwas vor, zugriff auf die incyte-datenbank und sequenzierung eines nicht genannten genoms. mal gespannt, was da in der nächsten zeit auf mich als alleinunterhalter zukommt.

gruß tgfn

[Brocker2000]

Hi Leute
habe crxa schon seit geraumer Zeit und werde sie nicht vor 150$ verkaufen sihe abgx.
Schaut euch doch mal www.corixa.com an steht eigentlich alles drin.
Schaun wir mal was sonst noch alles kommt. Für mich steht jedenfalls fest die Biotechbranch könnte die nächste
Internetbranch werden und man muß drin sein befor alle anderen es tun.
Also machen wir es wie Kostolani kaufen und schlafen legen auf bald
Brocker2000

[tgfn]

hallo brocker2000

war schlafen, dann hat mich der intraday-chart aufgeweckt.grauslig
gruß tgfn

[Brocker2000]

hi tgfn

schau dir mal abgx an. sehe bei corixa ähnlichen verlauf. also nerven behalten
und gut ding will weile haben
bye brocker2000

[tgfn]

hallo

steht bereits ganz dick auf der watchliste, ebenso wie medarex. sind mir aber in letzter zeit schon zu gut gelaufen. ich warte auf eine korrektur, falls sie denn jemals kommt.

gruß tgfn

[tgfn]

schreib ich eben an mich selber


hallo tgfn

du hast jetzt in weniger als einem monat 100% mit corixa gemacht. heute schon wieder über 20%. aber es interessiert ja keine sau.

gruß tgfn

[pollyanna]

Hallo tgfn,

gratuliere Dir zu der guten Performance mit corixa.
Die Story gefällt mir sehr gut, aber ich habe mich dann doch für
Curagen entschieden. Da kenne ich mich besser aus. Schau dir mal den
Chart an. Könnte auch für einen erfolgsverwöhnten wie dich interssant
sein. Einen thread zu posten spar ich mir. Ich glaube ich habe nicht
soviel Ausdauer mit Monologen wie du.

Mach weiter so
Gruß pollyanna

[tgfn]

hallo pollyanna

danke danke. curagen läuft ja auch sehr schön. habe übrigens so ziemlich zeitgleich ein posting an dich in den lachman-fred gesetzt. curagen schau ich mir nachher mal an. so langsam verliert man ja den überblick über die ganzen biotechs. von corixa habe ich übrigens heute die hälfte verkauft, wollte ich der fairnis-halber mitteilen. hat überhaupt nichts mit corixa zu tun, ich mache das eigentlich immer, wenn ein wert in so kurzer zeit um 100% zugelegt hat. das ist zwar vom logischen standpunkt aus gesehen nicht die rationalste entscheidung, es tut aber der psyche unheimlich gut.

gruß tgfn

[pollyanna]

Hallo tgfn,

"ich mache das eigentlich immer, wenn ein Wert in Kurzer Zeit 100%
gemacht hat"
Ich träume davon auch mal so einen spruch loszulassen.
Aber ich bin erst seit knapp 1 Jahr an der Börse tätig und hab die
meiste Zeit mit sogenannten Blue Chips vergeudet, wie wohl die meisten
Anfänger. Vielleicht gelingt es mir ja mit den Biotechs.

Zu corixa. Anscheinend haben die Fondmanager die Ergebnisse der
klinischen Studie Phase III von Melacine falsch verstanden.(yahoo)
Aber das wird schon und dann gehts wieder weiter aufwärts.

Gruß pollyanna

[tgfn]

hallo pollyanna

naja, allzugut sind die ergebnisse ja auch nicht. ein fünftel mehr leute haben überlebt, ich denke, an der börse wird etwas mehr erwartet. ist aber auch kein komplett negatives ergebnis, sonst wäre corixa 20-40% in den keller gerauscht.
ich habe corixa übrigens nicht wegen der melacine-sache gekauft. da habe ich eher so den eindruck, daß man melacine halt noch so mitschleppt (melacine wurde ursprünglich von ribi entwickelt, ribi wiederum wurde von corixa übernommen).
das mit den 100% ist so eine sache. ich bin selber erts seit ca. 1,5 jahren an der börse (nach 1jahr trockentraining). ich bin zufällig zu etwas kohle gekommen, die ich dann in daimler und ein paar neue markt-werte investiert habe. kurz danach (anfang 99)ging dann ähnlich wie zur zeit am neuen markt die post ab, und da hatte ich einen wert,der zuerst um 200% gestiegen ist, um mir danach 50% verlust zu bringen. sowas prägt, und bei 100% in 3 wochen werde ich immer unruhig. ich weiß bis heute noch nicht, ob ich bisher einfach glück an der börse habe, oder ob ich einen riecher für gute werte habe. das letztere wäre mir lieber.
war ja ein richtiger schreibanfall


viele grüße tgfn

[pollyanna]

Hallo tgfn,

zumindest was die Biotech-Aktien angeht bestimmt das letztere. Denn
ich habe noch nicht viele freds gefunden wo so gründlich recherchiert wurde wie
hier. Oft findet man nur Gerüchte, Spekulationen und Pushversuche.

Gruß pollyanna

[BullAuge Web]

Hallo tgfn !


Interessanter und gut recherchierte Geschichte von Dir.
Siehst du den Kurs von Corixa zur Zeit als Einstiegskurs ?


BullAUge

[tgfn]

hallo bullauge

wenn ich das wüßte. wenn der biotech-hype so weitergeht wie bisher, kann man nahezu blind alles kaufen, wo irgendwie bio draufsteht. die sache mit corixa ist die, daß ihre pipeline relativ gut "gestaffelt" ist, d.h. die produkte von corixa befinden sich in verschiedenen klinischen phasen. damit gibt`s auch schön gestaffelt news, die den kurs am laufen halten können. Die neuen kooperationen mit incyte und genset geben natürlich raum für jede menge phantasie, obwohl wahrscheinlich noch keiner weiß, auf was das ganze hinaus laufen wird. Gefühlsmäßig denke ich, daß corixa nach den nicht ganz so guten ergebnissen der melacine-trials noch etwas nachgeben kann. Auf der anderen seite steht der momentane biotech-hype, und die wertung der prudential-securities als strong buy. Prudential vergleicht corixa aufgrund seiner "antigen discovery-platform" mit abgenix und medarex. Kursziel sei 85$, wobei corixa gegenüber medarex und abgenix immernoch 45% billiger wäre. Kann leider die kurzanalyse nicht einstellen, weil sie in adobe acrobat ist. Nachzulesen unter multexinvestor.com, dort corixa eingeben und unterprudential zum free-trial registrieren lassen.

Gruß tgfn

[tgfn]

hallo

hoffe, daß keiner von euch gerade heute in corixa gegangen ist. gefühlsmäßig lag ich zwar richtig, aber nützen tut das natürlich auch nichts. zu allem überfluß wurden heute komplett fast alle biotechs runtergeprügelt, sodaß man sagen kann, daß der rückgang zur hälfte dem markt und zur anderen hälfte wohl der melacine-meldung zuzuordnen sind

gruß tgfn

[pollyanna]

Hallo tgfn,

es geht ja schon wieder aufwärts. Wenn auch der candlestick von heute
nicht gerade bullish ist. Jetzt verstehe ich dich besser mit deiner
100% Sicherung! Ich hoffe du hast was in Curagen reingesteckt.

gruß pollyanna

[tgfn]

hallo pollyanna

in curagen bin ich noch nicht drin. ich habe einen teil des corixa-verkaufs auch gebraucht, um einen anderen kauf (ich habe mir mit nordasia meinen allerersten fonds zugelegt, und das auch noch auf kredit) abzudecken. zur zeit ist es mir viel zu heiß, um auf kredit zu spekulieren.
die news von curagen wird meiner ansicht nach von wenigen leuten richtig verstanden. für sich alleine ist sie zunächst mal ohne "praktischen" wert, d.h. es wurde nicht das 20ste neue medikament gegen krebs entdeckt. klarist aber auch, das der nächste schritt in der biotechnologie nach der aufklärung der sequenz des menschl. genoms über proteine und ihr zusammenwirken im organismus ablaufen wird. wer da wie curagen ein paar eisen im feuer hat, wird die ganzen celeras und hgsi`s in der zukunft abhängen.
momentan tue ich mich schwer, mir was neues zu kaufen, ich befürchte, daß es so nicht mehr viel länger weitergehen kann. allerdings hängen meine crash-befürchtungen immer mit dem stand meines depots zusammen, sollte man also vielleicht nicht zuviel darauf geben.

gruß tgfn

[Huggy]

Hallo zusammen, bin in Corixa engagiert seit knapp 32 EUR. Das ist knapp 5 Wochen her. Bisher hat sich der Kurs sehr gut entwickelt und wird sich meiner Meinung nach auch weiter gut entwickeln. Jeder der inBiotechs investiert, sollte von den "Großen" (Millennium, Human Genome, Celera, Incyte, Affymetrix) aber auch von den kleineren Unternehmen welche an Bord haben. Deshalb mein Tipp an Euch: Wer nicht schon in Corixa engagiert ist, sollte es nunmehr tun. Der Bekanntheitsgrad wird weiter steigen, die Homepage gibt gute Infos, und meiner Meinung nach stimmt auch der Chart. Aber auch wenn der Kurs in kürze über 100 EUR steigt gilt mein Rat: Halten und nicht verkaufen. Gruß Euer Huggy

[tgfn]

hallo

vor zwei wochen wäre der kurs nach dieser meldung um 20%in die höhe geschossen. heute geht`s dafür um 30% nach unten. verstehs wer will.

Tuesday March 21, 8:06 am Eastern Time

Company Press Release

SOURCE: Corixa Corporation

Corixa and Abgenix Form Alliance to Discover And Develop Therapeutic
Monoclonal Antibodies

Multi-Product Collaboration to Target Autoimmune Diseases, Cancer and Infectious Diseases

SEATTLE, March 21 /PRNewswire/ -- Corixa Corporation (Nasdaq: CRXA - news), a research- and development-based biotechnology company, today
announced a collaboration with Abgenix, Inc. (Nasdaq: ABGX - news) to discover and develop human monoclonal antibodies against selected targets from Corixa`s
library of proprietary autoimmune disease, cancer and infectious disease antigens.

Under the terms of the agreement, Corixa will contribute three targets initially and up to six targets a year during the six-year agreement. Abgenix will contribute its
XenoMouse(TM) technology to the collaboration to generate, screen and characterize human monoclonal antibodies directed against Corixa`s antigens. Corixa, and
in some cases Abgenix, will then be responsible for determining whether the characterized antibodies have an immunotherapeutic effect in tissue culture experiments
and in animal models of human disease.

When antibodies are jointly determined to be worthy of clinical investigation, Corixa and Abgenix will hold a closed auction between the two parties for the rights to
develop the specific antibody-based product. The company with the winning bid will pay the bid amount in cash to the other company and will be responsible at that
point in time for all product development expenses and decisions. The non-development company will receive a share of future product development milestone
payments and a small royalty on future product sales.

``We are pleased to be entering into this broad-based collaboration with Abgenix,`` said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. ``We
have been impressed with Abgenix`s XenoMouse technology and view this innovative collaboration as a novel means of capitalizing on Corixa`s and Abgenix`s
capabilities to create what we believe will be a powerful product development engine for both companies. The auction structure of the relationship provides a
pre-determined split of downstream product development rights and benefits for all eventual products. The relationship allows each company to develop those
products that it finds most interesting or of greatest strategic value, in keeping with the partners` capabilities and financial resources at the time. This agreement further
extends the reach of immunotherapeutic products powered by Corixa technology.``

``Corixa has assembled a wide range of antigen discovery technologies that distinguish the company from other vaccine developers,`` said R. Scott Greer, president
and CEO of Abgenix. ``We believe that the marriage of Corixa`s antigens with our XenoMouse technology for rapid generation of fully human monoclonal antibodies
represents an exciting opportunity for both companies. We look forward to a productive relationship that could result in the discovery and commercialization of
multiple novel products for use in the treatment of autoimmune disease, cancer and infectious disease.``

The collaboration will be managed by a joint steering committee made up of an equal number of representatives from both companies. The steering committee will be
responsible for acceptance of Corixa antigens into the partnership, resource allocation, and determination of which resultant antibodies pass through to the auction
process.

About Corixa

Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by
understanding and directing the immune system. Corixa applies its expertise in immunology and its proprietary technology platforms to the discovery and development
of vaccine and other antigen-based products. The company partners with innovative developers and marketers of pharmaceuticals and diagnostic products to make
its products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton,
Mont. and Redwood City, Calif. For more information, please visit Corixa`s website at www.corixa.com or call the company`s investor relations information line at
1- 877-4CORIXA (1-877-426-7492).

Forward-Looking Statements

Except for the historical information presented, certain matters discussed in this press release are forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Such
risks and uncertainties include risks associated with product discovery and development as well as risks detailed from time to time in Corixa`s public disclosure filings
with the U.S. Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended December 31, 1999, and the
Company`s Registration Statement on Form S-3, filed on March 7, 2000. Copies of Corixa`s public disclosure filings with the Securities and Exchange Commission
(SEC) are available from its investor relations department.

SOURCE: Corixa Corporation

More Quotes
and News:
Abgenix, Inc (NasdaqNM:ABGX - news)
Corixa Corp (NasdaqNM:CRXA - news)
Related News Categories: biotech, medical/pharmaceutical


gruß tgfn

[tgfn]

hallo

wieder mal was neues zu corixa.ist deshalb so ziemlich der einzige wert in meiner bio-watchlist, der heute ein nennenswertes plus aufweist.


Home - Yahoo! - Help






[ Business | US Market | By Industry | IPO | AP | S&P | International | PRNews | BizWire | CCN ]



Tuesday April 11, 8:02 am Eastern Time

Company Press Release

Corixa Receives U.S. Patent On AnervaX.RA Vaccine for the Treatment of
Rheumatoid Arthritis

SEATTLE--(BW HealthWire)--April 11, 2000--Corixa Corporation (Nasdaq:CRXA - news), a research- and
development-based biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has
issued the Company a patent covering its AnervaX.RA(TM) rheumatoid arthritis (RA) vaccine.

Rheumatoid arthritis is a crippling disease, affecting an estimated 2.5 million Americans and a similar number of people worldwide. The patent, U.S. Patent Number
6,045,796, entitled ``Vaccination with Peptide of MHC Class II Molecules for Treatment of Autoimmune Disease,`` includes claims covering the composition of the
AnervaX.RA vaccine, as well as use of the vaccine to treat rheumatoid arthritis.

``This patent issuance represents continued advancement of our autoimmune disease efforts, building on our acquisition of Anergen in February 1999,`` said Steven
Gillis, Ph.D., chairman and chief executive officer of Corixa. ``The continued clinical development of our AnervaX.RA vaccine and the subsequent issuance of
patents for the potential vaccine are important steps toward commercialization of this novel approach to the treatment of arthritis.``

About Corixa`s AnervaX.RA Vaccine

AnervaX.RA vaccine is a synthetic 20-amino acid peptide sequence (amino acids 57-76) from the Beta chain of the specific MHC class II molecules genetically
linked to RA, and includes a ``shared epitope,`` that is common to approximately 90 percent of RA patients. In autoimmune diseases like rheumatoid arthritis, the
body erroneously recognizes components of cells or tissues as foreign antigens. These autoantigens are presented to the immune system by disease-linked MHC
class II molecules on the surface of antigen-presenting cells (APC). The vaccine is designed to act as a therapeutic vaccine stimulating the production of a neutralizing
immune response that prevents the autoimmune disease cascade by specifically blocking the presentation of self-antigen by disease-linked MHC molecules to
autoreactive T cells that cause rheumatoid arthritis, potentially halting the progression of the disease. In a Phase I/II study, the vaccine provided sustained clinical
benefit for up to twelve weeks after the last injection in a substantial proportion of patients with long-standing active RA, and had a low frequency of side effects. The
peptide vaccine is one application of the AnervaX(TM) technology platform. Other applications include a peptide vaccine for the treatment of Type I diabetes, which
is in pre-clinical development.

About Corixa

Corixa is a research- and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by
understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated
vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. The company partners with numerous developers and marketers of
pharmaceuticals and diagnostic products with the goal of making its potential products, Powered by Corixa(TM), available to patients around the world. Corixa was
founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. For more information, please visit
Corixa`s website at www.corixa.com or call the company`s investor relations information line at 877/4CORIXA or 877/426-7492.

Forward Looking Statements

Except for the historical information presented, the matters discussed in this press release are forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Such risks and
uncertainties include the failure of the AnervaX.RA vaccine to progress in clinical trials, adverse patient responses to the vaccine or the failure to prove safe or
efficacious in the event of further clinical trials, and other risks detailed from time to time in the Corixa`s public disclosure filings with the U.S. Securities and Exchange
Commission (SEC), including the Annual Report on Form 10-K for the fiscal year ended December 31, 1999, and the Company`s Registration Statement on Form
S-3/A, filed on April 7, 2000. Copies of Corixa`s public disclosure filings with the Securities and Exchange Commission (SEC) are available from its investor
relations department.

Contact:

Corixa Corporation
Investor Relations
Jim DeNike, 206/754-5716
[e-mail]
or
FitzGerald Communications Inc.
Media Relations
Jesse Ciccone, 415/986-9500
[e-mail]



More Quotes and News:
Corixa Corp (NasdaqNM:CRXA - news)
Related News Categories: biotech, health care, medical/pharmaceutical



Help


Copyright © 2000 Yahoo! All Rights Reserved. Privacy Policy - Terms of Service
Copyright 2000 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user`s personal
reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving ina
public database, redistributing via a computer network or in a printed form.
Questions or Comments?


gruß tgfn

[puhvogel]

Hmmm...
Ein starker Kursverfall bei hohen Umsätzen bei einem Biotechwert, dessen Hauptprodukt bald von einem Gremium beurteilt wird.

[toller]

Anstieg gestern:

Among the day`s biggest percentage gainers was Corixa`s stock, which rose $1.39, or 13 percent, to $12.30. Analyst Mark Monane at Needham & Co. said a Corixa-sponsored conference this week highlighted the promise of medications the company is developing, including experimental cancer treatment Bexxar.

Back in March, Corixa (CRXA: news, chart, profile) shares plunged after the Seattle-based company said the FDA had asked for more data about Bexxar. Such requests typically significantly delay marketing clearance for a product. But Monane said he believes Bexxar will ultimately win FDA approval and be on the market in late 2002. Monane said he`s also optimistic about Corixa`s other potential products, including a skin cancer treatment.

"Corixa has the scientific and management expertise to bring drugs to market," Monane wrote in a note to clients.

[toller]

was geht heute?

Amersham to market Corixa drug in Europe
(UPDATE: Adds detail from statement, background)

LONDON, Oct 29 (Reuters) - British healthcare group Amersham Plc said on Monday it had agreed to market Bexxar, a treatment for non-Hodgkin`s lymphoma being developed by Corixa Corp (NasdaqNM:CRXA - news), in Europe.

Non-Hodgkin`s lymphoma is a form of cancer that affects the blood and lymph tissues. More than 40,000 patients are diagnosed with the disease in Europe`s five largest countries each year.

Under terms of the deal, Corixa will generate clinical trial data for Bexxar`s registration in Europe and Amersham will manufacture and sell it across the continent, though under a different name.

Amersham will also buy $15 million in Corixa common stock at a premium, which it did not disclose, and the rest of the company`s shares in the future as decided by Corixa.

In addition, it will pay Corixa multi-million dollar milestone payments when European regulators approve Bexxar and the drug achieves undisclosed sales volumes.

Amersham will also pay Corixa undisclosed royalties on all future sales of its products in Europe.

Bexxar, a radioimmunotherapy treatment that combines monoclonal antibody and radiation therapy, is currently under review by the U.S. Food and Drug Administration.

Corixa has a marketing and development agreement for Bexxar in the United States with UK drugs giant GlaxoSmithKline Plc (quote from Yahoo! UK & Ireland: GSK.L).

Amersham, which beat analysts` forecasts with a 24 percent rise in first-half profit, is due to release a third-quarter trading update on Tuesday.

At Friday`s close of 616 pence, its shares had outperformed the FTSE All-Share health sector (^FTMA - news) by around 11 percent since the start of the year

[toller]

Press Release
SOURCE: Corixa Corporation; GlaxoSmithKline
Durable Responses Reported with Bexxar Alone or In Sequential Therapy for Low-Grade Non-Hodgkin`s Lymphoma
Research Presented at ASH
ORLANDO, Fla., Dec. 11 /PRNewswire/ -- According to studies presented at the 43rd annual meeting of the American Society of Hematology (ASH), Bexxar® (tositumomab and iodine I 131 tositumomab), an investigational radioimmunotherapy being studied for the treatment of low-grade or transformed low-grade non-Hodgkin`s lymphoma (NHL), provides durable, long-term responses when used either alone or following chemotherapy. Multiple presentations suggest that Bexxar, currently under review at the U.S. Food and Drug Administration (FDA), may offer an important new treatment option for relapsed or refractory NHL patients, and in particular for patients whose prognosis is usually very poor.

Reports of Durable, Objective Responses

Analysis of data on 582 patients with relapsed, refractory low-grade or transformed low-grade NHL who received Bexxar in clinical trials from 1990- 2000, by John Leonard, M.D., clinical director, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York, and his colleagues, showed that Bexxar produced an overall response (defined as a reduction of at least 50 percent in overall tumor burden) in 57 percent of patients, half of whom remained in remission for 14.3 months or more [ASH Abstract #2527]. Furthermore, 28 percent of all patients showed a complete response (total elimination of disease confirmed by clinical or radiological evaluation) to Bexxar therapy, half of whom remained in remission for 4.8 years or longer. The average follow-up was 1.3 years with a maximum of 8.5 years.

``These results provide further evidence that Bexxar produces durable responses in patients with either low-grade or transformed low-grade NHL,`` said Dr. Leonard.

Novel First-Line Triple Modality Therapy

To evaluate a new approach to previously untreated NHL, investigators treated 35 patients in a clinical trial of ``triple modality`` therapy, the combination of chemotherapy (fludarabine), radiation (Iodine-131) and a monoclonal antibody (tositumomab) [ASH Abstract #3505]. All patients (100 percent) in the trial exhibited an investigator-assessed response to the treatment, with 77 percent achieving a complete response. After a median of 23 months of follow-up, more than half of the patients were showing no signs of disease progression.

``We are encouraged by the results of this study and the apparent utility of this triple modality approach using fludarabine and Bexxar radioimmunotherapy,`` said Dr. Leonard. ``Combination regimens have been successful in many cancers and offer new strategies for patients with lymphoma.``

The triple modality regimen consisted of three cycles of fludarabine followed by Bexxar, administered six to eight weeks later, for patients with previously untreated low-grade NHL. Ninety-seven percent of the participants were classified as stage III (widespread disease to both sides of the diaphragm), or stage IV (spread outside of the lymph system to one or more organs and the bone marrow). The patient population ranged in age from 25 to 82.

The hematologic side effects of the triple modality therapy were principally decreases in white blood cell counts that responded to supportive care. Three patients were hospitalized for neutropenic fever (one after fludarabine and two after fludarabine and Bexxar).

``This novel approach produces a high response rate in initial therapy for low-grade non-Hodgkin`s lymphoma,`` concluded Dr. Leonard. ``We have also found that by using fludarabine to debulk or reduce a patient`s tumor burden, including tumor in the bone marrow, we can expand the number of patients who can benefit from Bexxar therapy.``

Triple modality therapy, combining various chemotherapies with Bexxar, is being investigated for the treatment of other types of non-Hodgkin`s lymphoma. Results from one such study, a Phase II clinical trial of CHOP, a standard combination chemotherapy regimen, followed by Bexxar, for treatment of newly diagnosed follicular NHL, were also reported at ASH by researchers affiliated with the Southwestern Oncology Group (SWOG) [ASH Abstract #3504]. In this study, 80 percent of the 71 patients evaluated following the sequential therapy had achieved an objective remission, either having a complete response (52 percent) or a partial response (28 percent). Grade 4 toxicities were reported in 38 percent of the 88 evaluable patients who had received CHOP. Thirteen percent of 60 presently evaluable patients who went on to receive Bexxar experienced additional Grade 4 toxicity. In 17 patients (24 percent), the addition of Bexxar to CHOP improved the overall best response, either from a partial to a complete response (15 patients or 21 percent) or from an unconfirmed to a confirmed complete response (2 patients or 3 percent). The investigators reported that ``the addition of I-131-tositumomab [Bexxar] radioimmunotherapy to 6 cycles of CHOP chemotherapy is feasible, well- tolerated and efficacious.``

Importance of Radiation Component of Bexxar Therapy Demonstrated

Investigators also presented data that clearly demonstrated the clinical utility of the radioactive component in Bexxar [ASH Abstract #3503]. This study, a randomized, open label, multicenter clinical trial of 78 patients treated at nine sites investigated the safety and efficacy of treatment with either Bexxar or its unlabeled antibody component, tositumomab. Seventeen percent of patients enrolled in this trial presented with transformed disease, a particularly difficult prognostic factor with respect to survival and response. Independently assessed confirmed overall responses were observed in 55 percent of the patients treated with Bexxar and 17 percent of patients treated with two doses of tositumomab. Confirmed complete responses were achieved in 33 percent of patients treated with Bexxar compared to 8 percent of patients treated with tositumomab.

The median duration of confirmed responses for patients treated with Bexxar has not been reached, whereas half of the patients treated with unlabeled tositumomab had relapsed after 18 months. The study allowed patients who did not respond or who relapsed after unlabeled tositumomab to crossover to receive Bexxar. Of the 19 patients who did so, 68 percent had a confirmed response and 42 percent had a confirmed completed response.

``We have demonstrated that radiolabeling with I-131 provides significant therapeutic benefits over an unlabeled anti CD-20 antibody,`` said Mark S. Kaminski, M.D., professor of internal medicine and co-director of the leukemia/lymphoma bone marrow transplant program at the University of Michigan Cancer Center.

Hematologic toxicity was observed in a greater number of Bexxar patients than tositumomab patients. ``In our assessment, the greater therapeutic activity of Bexxar outweighed the lower toxicity observed for the unlabeled antibody,`` said Dr. Kaminski.

Overall Bexxar Hematological Toxicity Reported

Dr. Kaminski also presented an analysis of hematologic toxicity following treatment with Bexxar based on data from 677 previously treated patients with relapsed or refractory low-grade NHL and 76 previously untreated patients [ASH Abstract #1433]. He and his colleagues found that Grade 4 neutropenia, anemia, and thrombocytopenia occurred in 16 percent, 2 percent, and 3 percent of patients respectively, with serious infections reported in 5 percent and Grade 3 or 4 bleeding events in only 1 percent. Twenty-three percent of these previously treated patients required some form of supportive care (such as growth factors or transfusions) for hematologic side effects. Hematologic toxicity was less frequent in previously untreated patients. No patients in this cohort exhibited hematologic toxicity that required treatment with either growth factors or transfusions. The researchers concluded that the hematologic side effects in patients who received Bexxar were manageable and reversible, and the use of supportive care was uncommon.

``Furthermore, because Bexxar therapy is administered as a single course of treatment, it avoids the repeated and cumulative treatment related toxicity that may result from successive cycles of standard chemotherapy,`` said Dr. Kaminski.

Non-Hodgkin`s Lymphoma

Non-Hodgkin`s lymphoma is a form of cancer that affects the blood, bone marrow and lymphatic tissues. NHL currently is the sixth leading cause of death among cancers in the United States and has the second fastest growing mortality rate. According to statistics from the National Cancer Institute (NCI), approximately 300,000 people are afflicted with NHL in the United States alone. Of that total, the NCI estimates that approximately 140,000 people have low-grade NHL or transformed low-grade NHL, an aggressive, difficult to treat, and particularly deadly form of the disease. Typically, the response rates and duration of response for NHL patients decline with each subsequent course of chemotherapy.

Bexxar therapy combines the targeting ability of a monoclonal antibody and the therapeutic potential of radiation, with patient-specific dosing. The radiolabeled monoclonal antibody attaches to the target molecule CD20 found on NHL cells, thereby mediating an immune response and delivering a dose of Iodine-131 radiation to tumor cells. Bexxar is the only investigational NHL therapy that is precisely dosed based on individual drug clearance rates, resulting from such factors as tumor size and metabolism. Patient-specific dosing allows for a predictable level of therapeutic radiation to be delivered to each patient and may enhance the tolerability of the treatment.

[toller]

Hallo und gutes neues jahr.

hat jemand was aktuelles zu corixa? da ist heute in deutschland mal wieder handel angesagt. scheint was im busch zu sein.

toller

[Blaui]

Musterdepotaufnahme im Aktionär. Gruss Blaui.

[toller]

? woher hast du das denn?

gruß

[tommihe]

.







schaut auch technich gar nicht so schlecht aus!

[tommihe]

tja , das war nicht der gewuenschte Chart, sorry.


Mal abgesehen von der Technik hat Corixa eine recht gute
Produktpipeline.
Phase III Detox Breast Cancer Vaccine
Phase III Melacine Melanoma
Phase III MPL Vaccine Herpes Virus Type2 genital
Phase II Anerva XRA Rheumatoid Arthritis
Phase II Anergi X Rheumatoid Arthritis
Phase I/II Anergi XMS Multiblesclerosis
Phase I/II Anergi XRA Rheumatoid Arthritis
BLA/NDA Bexxar Lymphoma
Phase I Her2 Vaccine Breast Cancer,Ovarian Cancer
Pre Clinic Leif Cancer ,Infectious Disease

Market Metastron Metastasis,Cancer,Bone Cancer

meiner Meinung nach durchaus Luft bis 22-23EU!

[toller]

Stimmt tatsächlich: corixa ist im "Der Aktionör, Biotech-Depot".

...damit habe ich allerdings nicht so tolle erfahrungen bzw. versuche solche sachen zu ignorieren. man kann davon ausgehen, dass förtsch schon lange vorher drin ist.

Glücklicherweise handelt es sich bei corixa nicht um so einen NM-Zocker-Wert, der Kurs wird in USA gemacht, und darauf hat förtsch bei einem durchschnittlichen handelsvolumen von 294.000 Stück/Tag wohl kaum einfluss...

also nur zur information:

Aktie/WKN/Stück/Kauf/Kurs 07.01./ ± / %
Corixa 909707 600 02.01.2002 16,80 18,10 7,7 %
Xoma 871239 1.250 18.12.2001 8,90 10,80 21,3 %
Vertex 882807 700 18.12.2001 27,50 27,40 -0,4 %
Biomarin 924801 1.000 20.11.2001 14,40 15,20 5,6 %

Startkapital am 01.01.2002 113.338,50
Aktien 58.740,00
Cash 54.813,50
Depotwert aktuell 113.553,50
Gewinn/Verlust seit 01.01.2002 0,2 %

[toller]

wieder jede menge neue nachrichten zu Corixa unter

finance.yahoo.com ("crxa" eingeben).

Interessant ist die Kombination mit einem Med. von Rhein Biotech.

leider wurden die guten kurse heute morgen in FSE (max. 19.4 Euro) mal wieder durch die NAchkäufer des Förtsch-Muster-Depots gemacht, so wie in den letzten tagen auch vermute ich. d.h. die kurse gehen dann auch immer schnell wieder auf ein normalniveau runter.

Mal sehen wies in USA läuft heute, momentan gesatltet sich der verlauf eher unspektakulär.

[toller]

nachdem wir gestern morgen so tolle nachrichten in USA hatten, ist wohl am abend ne sehr enttäuschende dazu gekommen:

bexxar ist schon wieder nicht auf der liste!

Schade. hätte verkaufen sollen gestern zu 19.4, und heute morgen bei 16.6 wieder einsteigen.

Corixa says Bexxar won`t get FDA review in Feb.
SEATTLE, Jan 9 (Reuters) - Biotech company Corixa Corp. (NasdaqNM:CRXA - news) said on Wednesday that a Food and Drug Administration panel will not be able to review next month the safety and efficacy of the company`s drug Bexxar for the treatment of low-grade non-Hodgkin`s lymphoma.
ADVERTISEMENT



Corixa said the FDA advised the company that, as a result of the extensive amount of material submitted in response to the agency`s complete review letter and subsequent discussions, February would not be an optimal time for discussion at the Oncologic Drugs Advisory Committee.

Corixa said the FDA has assured the company that it is continuing to work diligently on its review of Bexxar. The panel`s next meeting is tentatively scheduled for June 6-7, but the agenda has not been set.

Although Corixa can provide no assurances, the company is hopeful that the safety and efficacy of Bexxar will be reviewed at that time. Bexxar is being co-developed by Corixa and GlaxoSmithKline Plc. (quote from Yahoo! UK & Ireland: GSK.L)

``Corixa remains committed to Bexxar and the promise it holds as a potential therapeutic for non-Hodgkins lymphoma patients,`` Corixa Chairman and Chief Executive Steven Gillis said in a statement. ``We will continue to assist the FDA in their ongoing review of our Biological License Application and look forward to ODAC review of our submission as soon as possible.``

[toller]

diese info politik ist ja super nett:

erst ne ganz gute meldung, alles wartet auf steigende kurse, dann nach börsenschluss in USA noch die Hammer meldung dass bexxar es mal wieder nicht geschafft hat. shit shit.

[puhvogel]

Der Gutachtertermin ist weiter verschoben worden, weiter nichts.
CRXA mag ich trotzdem nicht.

[toller]

naja, "...weiter nix" ist ja wohl ein wenig untertrieben. der nächste termin liegt nicht vor Juni. das ist lang. und so hat IDEC mal wieder gelegenheit die jüngste Verzögerung bei Zevalin aufzuholen, und die sind eh schon einen schritt weiter

[wasweissichdenn]

corixa geht gerade vorbörslich an der nasdaq um ca. 13% richtung süden. ist da auch was im busch????